Loading ...
Posted on October 5 , 2013 by rjfacilitator The Rand Corporation , the National Institute of Health , and the International Institute of Restorative Practice have come togetherto createa robust “ randomized controlled trials ” study
Feng J. ProbioticspreventHirschsprung ’s disease - associated enterocolitis : a prospective multicenter randomized controlled trial
qualitative and quantitative formative researchleadingto a randomized controlled feasibility trial of a video game - based physical activity intervention
children 's television browsingto preventunhealthy weight ... a randomized controlled trial
Behavior intervention : The platform allowsto ... setup randomized controlled trials through a built - in randomized assignment
The results with wearables at Cedars - Sinaipromptedimmediate work on a randomized - controlled trial
The Feasibility of using Snoezelen within a Palliative care daysettingA Randomized Controlled Trial investigating the potential
Failure of natalizumabto preventrelapses in neuromyelitis optica In - Depth [ randomized controlled trial
excessive gestational weight gain and promote postpartum weight loss in overweight and obese womento preventexcessive gestational weight gain and promote postpartum weight loss in overweight and obese women
in the studiesresultsin the studies
to test superiority of rifampin plus other protocol - specified antimicrobial therapy compared to the “ other protocoldesignedto test superiority of rifampin plus other protocol - specified antimicrobial therapy compared to the “ other protocol
to evaluate the safety and efficacy of BVS compared with CoCr - EESdesignedto evaluate the safety and efficacy of BVS compared with CoCr - EES
to assess the efficacy and safety of roxadustat vs. an erythropoietin - stimulating agent ( ESAdesignedto assess the efficacy and safety of roxadustat vs. an erythropoietin - stimulating agent ( ESA
to assess the efficacy and safety of roxadustat vs. epoetin alfadesignedto assess the efficacy and safety of roxadustat vs. epoetin alfa
to enroll approximately 50 patients with hemophilia A or B with inhibitors receiving prior on - demand therapydesignedto enroll approximately 50 patients with hemophilia A or B with inhibitors receiving prior on - demand therapy
to enroll approximately 100 patients with hemophilia A or B without inhibitors receiving prior on - demand therapydesignedto enroll approximately 100 patients with hemophilia A or B without inhibitors receiving prior on - demand therapy
to a different outcome [ 19leadto a different outcome [ 19